Abstract
The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
CNS & Neurological Disorders - Drug Targets
Title:From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
Volume: 11 Issue: 6
Author(s): Ana M. Sebastiao, Filipa F. Ribeiro and Joaquim A. Ribeiro
Affiliation:
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
Abstract: The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Export Options
About this article
Cite this article as:
M. Sebastiao Ana, F. Ribeiro Filipa and A. Ribeiro Joaquim, From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581074
DOI https://dx.doi.org/10.2174/187152712803581074 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Congenital Cytomegalovirus Prevention, Awareness and Policy Recommendations - A Scoping Study
Infectious Disorders - Drug Targets Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Maternal Exposure to Quetiapine: Effects on Structural Changes in Developing Brain and its Lasting Impact on Neurobehavioral Impairments in Rat Offspring
Current Psychopharmacology Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Metabotropic Glutamate and Cannabinoid Receptor Crosstalk in Periaqueductal Grey Pain Processing
Current Neuropharmacology CAR, The Continuously Advancing Receptor, in Drug Metabolism and Disease
Current Drug Metabolism N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity
Combinatorial Chemistry & High Throughput Screening Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Combined Virtual Screening Strategies
Current Computer-Aided Drug Design Editorial [Hot topic: Pharmacotherapies for Alcoholism: The Old and the New (Guest Editor: M. Foster Olive)]
CNS & Neurological Disorders - Drug Targets High Throughput Screening Methodologies Classified for Major Drug Target Classes According to Target Signaling Pathways
Combinatorial Chemistry & High Throughput Screening Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets